IN2014CN04127A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04127A IN2014CN04127A IN4127CHN2014A IN2014CN04127A IN 2014CN04127 A IN2014CN04127 A IN 2014CN04127A IN 4127CHN2014 A IN4127CHN2014 A IN 4127CHN2014A IN 2014CN04127 A IN2014CN04127 A IN 2014CN04127A
- Authority
- IN
- India
- Prior art keywords
- formula
- triazol
- 115the
- benzamide
- pharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
115The present invention relates to 2 (1 2 3 triazol 2 yl)benzamide and 3 (1 2 3 triazol 2 yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar Q and R to R are as described in the description to their preparation to pharmaceutically acceptable salts thereof and to their use as pharmaceuticals to pharmaceutical compositions containing one or more compounds of formula (I) and especially to their use as orexin receptor antagonists.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2011054976 | 2011-11-08 | ||
PCT/IB2012/056218 WO2013068935A1 (en) | 2011-11-08 | 2012-11-07 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04127A true IN2014CN04127A (en) | 2015-07-10 |
Family
ID=47258050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4127CHN2014 IN2014CN04127A (en) | 2011-11-08 | 2012-11-07 |
Country Status (27)
Country | Link |
---|---|
US (1) | US9150566B2 (en) |
EP (1) | EP2776430B1 (en) |
JP (1) | JP5718535B2 (en) |
KR (1) | KR101676930B1 (en) |
CN (1) | CN103917538B (en) |
AR (1) | AR088692A1 (en) |
AU (1) | AU2012335194B2 (en) |
CA (1) | CA2846568C (en) |
CL (1) | CL2014000659A1 (en) |
CY (1) | CY1117638T1 (en) |
DK (1) | DK2776430T3 (en) |
EA (1) | EA024106B1 (en) |
ES (1) | ES2572703T3 (en) |
HK (1) | HK1199022A1 (en) |
HR (1) | HRP20160678T1 (en) |
HU (1) | HUE029239T2 (en) |
IL (1) | IL232462A (en) |
IN (1) | IN2014CN04127A (en) |
MX (1) | MX343837B (en) |
MY (1) | MY167791A (en) |
PL (1) | PL2776430T3 (en) |
SG (1) | SG11201401665WA (en) |
SI (1) | SI2776430T1 (en) |
TW (2) | TWI565703B (en) |
UA (1) | UA112317C2 (en) |
WO (1) | WO2013068935A1 (en) |
ZA (1) | ZA201404189B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
NZ628491A (en) | 2012-02-07 | 2016-06-24 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
TWI510481B (en) | 2012-06-04 | 2015-12-01 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
JP2016510810A (en) | 2013-03-12 | 2016-04-11 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
UA119151C2 (en) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
PT3077389T (en) | 2013-12-03 | 2017-12-15 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
HUE040555T2 (en) | 2013-12-04 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
JP5907310B2 (en) * | 2013-12-13 | 2016-04-26 | 大正製薬株式会社 | Crystal form of oxazinane compound and process for producing the same |
JP2017024990A (en) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | Oxazolidine and oxazinan derivative |
JP6323886B2 (en) | 2014-05-16 | 2018-05-16 | 国立大学法人 東京大学 | Depressant |
EP3180332B1 (en) | 2014-08-13 | 2021-10-27 | Eolas Therapeutics Inc. | Difluoropyrrolidines as orexin receptor modulators |
WO2016095205A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
CN104557744B (en) * | 2014-12-23 | 2017-04-12 | 广东东阳光药业有限公司 | Preparation method of triazoie compound |
WO2017088759A1 (en) | 2015-11-23 | 2017-06-01 | Sunshine Lake Pharma Co., Ltd. | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
AU2017217931B2 (en) | 2016-02-12 | 2020-10-22 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
CA3059394C (en) | 2017-05-03 | 2023-09-12 | Idorsia Pharmaceuticals Ltd | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
WO2020099511A1 (en) * | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
GB201901142D0 (en) * | 2019-01-28 | 2019-03-20 | Heptares Therapeutics Ltd | OX1 Antagonists |
EP4288432A1 (en) | 2021-02-02 | 2023-12-13 | Idorsia Pharmaceuticals Ltd | A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone |
TW202400149A (en) * | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
CN115947697A (en) * | 2022-12-28 | 2023-04-11 | 苏州汉德创宏生化科技有限公司 | Synthesis method of 3-oxomorpholine-4-carboxylic acid tert-butyl ester |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130432A (en) | 1990-12-21 | 1992-07-14 | Syntex (U.S.A.) Inc. | Process for preparing cyclic amines and intermediate products thereof |
CA2111957A1 (en) | 1991-06-27 | 1993-01-07 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
AU2002341123A1 (en) * | 2001-05-05 | 2002-11-18 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
WO2003002561A1 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
GB0124463D0 (en) * | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
KR100848747B1 (en) | 2004-03-01 | 2008-07-25 | 액테리온 파마슈티칼 리미티드 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
JP4582722B2 (en) | 2006-03-15 | 2010-11-17 | アクテリオン ファーマシューティカルズ リミテッド | Tetrahydroisoquinoline derivatives that improve memory function |
US8618102B2 (en) | 2006-07-14 | 2013-12-31 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
GB0620818D0 (en) | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
PE20081229A1 (en) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | DIAZEPAM OREXIN RECEPTOR ANTAGONISTS REPLACED |
CA2699328A1 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
PE20091010A1 (en) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | TETRAHYDROQUINOLINE DERIVATIVES |
JP2012506374A (en) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5-disubstituted piperidine orexin receptor antagonist |
JP2012506375A (en) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5-disubstituted piperidine orexin receptor antagonist |
US8466281B2 (en) | 2008-10-21 | 2013-06-18 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
KR20110091582A (en) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | N-{[(1r,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
CN102300858A (en) | 2008-12-02 | 2011-12-28 | 葛兰素集团有限公司 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] Hept-4-yl] Methyl}-2-heteroarylamine Derivatives And Uses Thereof |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
KR101859409B1 (en) | 2009-10-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS |
JP5847087B2 (en) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Fused heterocyclic compounds as orexin receptor modulators |
-
2012
- 2012-11-07 UA UAA201402001A patent/UA112317C2/en unknown
- 2012-11-07 TW TW105118634A patent/TWI565703B/en active
- 2012-11-07 HU HUE12791862A patent/HUE029239T2/en unknown
- 2012-11-07 EA EA201400553A patent/EA024106B1/en not_active IP Right Cessation
- 2012-11-07 MY MYPI2014701155A patent/MY167791A/en unknown
- 2012-11-07 PL PL12791862.1T patent/PL2776430T3/en unknown
- 2012-11-07 TW TW101141421A patent/TWI555747B/en active
- 2012-11-07 KR KR1020147014960A patent/KR101676930B1/en active IP Right Grant
- 2012-11-07 EP EP12791862.1A patent/EP2776430B1/en active Active
- 2012-11-07 SG SG11201401665WA patent/SG11201401665WA/en unknown
- 2012-11-07 JP JP2014540606A patent/JP5718535B2/en active Active
- 2012-11-07 CA CA2846568A patent/CA2846568C/en active Active
- 2012-11-07 MX MX2014005635A patent/MX343837B/en active IP Right Grant
- 2012-11-07 ES ES12791862.1T patent/ES2572703T3/en active Active
- 2012-11-07 WO PCT/IB2012/056218 patent/WO2013068935A1/en active Application Filing
- 2012-11-07 DK DK12791862.1T patent/DK2776430T3/en active
- 2012-11-07 AR ARP120104193A patent/AR088692A1/en active IP Right Grant
- 2012-11-07 IN IN4127CHN2014 patent/IN2014CN04127A/en unknown
- 2012-11-07 AU AU2012335194A patent/AU2012335194B2/en active Active
- 2012-11-07 SI SI201230556A patent/SI2776430T1/en unknown
- 2012-11-07 US US14/357,159 patent/US9150566B2/en active Active
- 2012-11-07 CN CN201280054325.7A patent/CN103917538B/en active Active
-
2014
- 2014-03-18 CL CL2014000659A patent/CL2014000659A1/en unknown
- 2014-05-05 IL IL232462A patent/IL232462A/en active IP Right Grant
- 2014-06-06 ZA ZA2014/04189A patent/ZA201404189B/en unknown
- 2014-12-11 HK HK14112452.0A patent/HK1199022A1/en unknown
-
2016
- 2016-06-14 HR HRP20160678TT patent/HRP20160678T1/en unknown
- 2016-06-15 CY CY20161100527T patent/CY1117638T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04127A (en) | ||
MX354102B (en) | Benzimidazole-proline derivatives. | |
UA108926C2 (en) | LibreOfficeKINASE PYRROLO[2,3-DEPENDENT INHIBITORS | |
MX2011011428A (en) | Sulfamoyl benzoic acid derivatives as trpm8 antagonists. | |
PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
ATE483707T1 (en) | 2-CYCLOPROPYLTHIAZOLE DERIVATIVES | |
TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
MX2010001338A (en) | Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions. | |
SG195106A1 (en) | Trpv4 antagonists | |
PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
MX2021004000A (en) | Piperidine cxcr7 receptor modulators. | |
WO2013190508A3 (en) | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
WO2011138265A3 (en) | Indole and indazole derivatives as orexin receptor antagonists | |
EA201300857A1 (en) | PYRAZOLES AS AN ANTAGONISTS CRTH2 | |
MX2009007429A (en) | Pyridine compounds and their use as p2y12 antagonists. | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
WO2010131192A3 (en) | Novel oxazolidinone derivatives and their use as orexin receptor antagonists | |
UA112586C2 (en) | BENZIMIDAZOLPROLINE DERIVATIVES | |
MX356499B (en) | Novel heteroarylamide derivatives having antiandrogenic properties. |